Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(27 sites)
Belgium
Antwerp University Hospital (UZA), Edegem, Edegem France
Hospital Center University Dijon Bourgogne (CHU Bourgogne), Dijon, Dijon Centre Hospitalier Universitaire (CHU) Bordeux, Bourdeaux Lille University Hospital, Lille Hôpital Edouard Herriot, Lyon, Lyon Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, France, Marseille Department of Digestive Oncology, CHU Saint Eloi, Montpellier, France/ ICM Cancer Institute at Montpellier, Montpellier Centre Hospitalier Universitaire de Nantes, Nantes I. Gustave Roussy, Paris, Paris Italy
Azienda USL IRCCS Di Reggio Emilia, Reggio Emilia, Reggio Emilia AOU Consorziale Policlinico di Bari - CROB Referrall Cancer Center of Basilicata, Bari IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - Irsì - Meldola, Meldola Istituto Europeo di Oncologia - Milano, Milan Digestive Disease Unit, Sant'Andrea University Hospital, ENETS Center of Excellence Rome, Rome, Italy., Roma Azienda Ospedaliera Universitaria Integrata Verona, Verona Spain
Hospital Universitario Virgen del Rocío, Seville, Andalusia ICO Institut Català d'Oncologia L'Hospitalet, L'Hospitalet de Llobregat, Barcelona Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Galicia Hospital General Universitario Gregorio Marañón, Madrid, Madrid Hospital Universitario Ramón y Cajal, Madrid, Madrid, Madrid Fundación Jiménez Díaz University Hospital, Madrid, Madrid Hospital Universitario 12 de Octubre, Madrid, Madrid Hospital Universitario Central de Asturias, Oviedo, Principality of Asturias Hospital Universitario y Politécnico La Fe, Valencia, Valencia Hospital Universitari Vall d'Hebron, Barcelona